Longtime Bay Area biotech follows up late-stage trial data with planned $175M stock sale


The company has racked up an accumulated deficit of more than $1 billion over its 32 years.

Previous Why an 84-year-old is inviting biotech to a golden age in cinema
Next Hobby Airport to add Velvet Taco, The Rustic and Houston-based eateries under new contract